2022年2月11日

對製藥行業的新技術進步感到好奇嗎?探索我們對全球1268家創業公司的分析，了解他們的藥理學解決方案如何影響您的業務!這份數據驅動分析的見解來自大數據和人工智能(AI)支持的StartUs insights發現平台，涵蓋全球2 093 000多家初創企業和規模。該平台為您提供了一個在特定領域的新興技術和相關創業公司的詳盡概述，隻需幾次點擊。下麵的全球創業熱圖揭示了我們在本研究中分析的1268家典型的創業公司和規模的分布。此外，本文還重點介紹了五家我們根據成立年份、地點、籌集資金等標準精心挑選的製藥初創公司。在這份報告中，你將探索這五家初創公司的解決方案。對於其他1263個藥理學解決方案的見解，請與我們聯係。總部位於英國的初創公司Antiverse使用機器學習優化藥物發現過程。這家初創公司的解決方案使用深度測序和計算技術來選擇可能被遺漏的DNA序列。 These sequences are clustered based on their binding score that is assigned according to the similarity of sequence behavior, providing a greater understanding of the disease. Antiverse’s method thus allows access to multiple drug formulations while requiring less time in comparison to traditional methods. Dalriada enables Small Molecule Discovery Founding Year: 2017 Partner with Dalriada for Accelerated Drug Discovery Canadian startup Dalriada advances small molecule drug discovery. It specializes in Target-to-IND stage drug discovery projects on small molecule development. The startup facilitates drug development in immuno-oncology, inflammation and immunology, cardiovascular and metabolic diseases, neuroscience, and anti-infectives. This approach minimizes turn-around times, allows full customization of R&D, and improves partner engagement. Epiodyne enhances Receptor Pharmacology Use this solution for Analgesic Development Epiodyne is a US-based startup that develops novel analgesics capable of treating neurobehavioral symptoms for brain disorders. The startup’s treatment modulates endorphin signaling and relieves the debilitating symptoms of serious brain disorders. Epiodyne’s technology also aids the determination of high-resolution structures of multiple opioid receptors. This optimizes the activity level of receptor types and mitigates the family and societal impacts of serious mental illness and neurodegenerative diseases. Apnimed develops Sleep Apnea Cure Founding Year: 2017 Partner with Apnimed for Sleep Disorder Treatment US-based pharma startup Apnimed makes oral medicines to treat Obstructive Sleep Apnea (OSA) and related disorders. The startup’s proprietary approach studies the key underlying neurobiological mechanisms and designs therapies that target the irregularities that lead to airway obstruction. The startup’s drug candidate, AD109, targets two neurochemical pathways that control the upper airway musculature during sleep. The medicine’s dual mechanism of action leads to upper airway dilation and improved respiration and oxygenation during sleep. This approach substantially improves the treatment of patients with symptomatic snoring. FOx Biosystems facilitates Therapeutic Drug Monitoring Founding Year: 2016 Use this solution for Biomolecular Interaction Analysis FOx Biosystems is a Belgian startup that develops a proprietary technology that uses the surface plasmon resonance (SPR) principle for biomolecular interaction analysis. The startup’s eponymous solution offers an accurate, fast, and convenient alternative to techniques currently used for therapeutic drug monitoring. Its biosensors accurately detect, quantify and measure the potency of the antibody of interest in a variety of sample matrices. This enables researchers to generate high-quality, cost-effective biomolecular data accurately and over a wide range of applications. Discover more Pharma Startups Pharma startups such as the examples highlighted in this report focus on proteomics, drug development, bioinformatics as well as deep learning, AI, and machine learning. While all of these technologies play a major role in advancing the pharma industry, they only represent the tip of the iceberg. To explore pharma technologies in more detail, simply let us look into your areas of interest. For a more general overview, download our free Pharma Innovation Report to save your time and improve strategic decision-making. Get your free Pharma Innovation Report We’ll deliver it straight to your inbox! First & Last Name*